

AUTHOR CORRECTION

Correction for Ingale et al., Hyperglycosylated Stable Core Immunogens Designed To Present the CD4 Binding Site Are Preferentially Recognized by Broadly Neutralizing Antibodies

Jidnyasa Ingale,^a Karen Tran,^b Leopold Kong,^c Barna Dey,^d Krishna McKee,^e William Schief,^{a,b} Peter D. Kwong,^e John R. Mascola,^e Richard T. Wyatt^{a,b}

Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA^a; IAVI Neutralizing Antibody Center at TSRI, La Jolla, California, USA^b; Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA^c; Laboratory of Viral Diseases, NIAID, NIH, Bethesda, Maryland, USA^d; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA^e

Volume 88, no. 24, p. [14002–14016](#), 2014. Page 14014, Acknowledgments: The following sentence should appear at the end of the first paragraph.

A portion of this work was supported by an American Foundation for AIDS Research Mathilde Krim Fellowship in Basic Biomedical Research (L.K.).

Citation Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT. 2015. Correction for Ingale et al., Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies. *J Virol* 89:6526.
[doi:10.1128/JVI.00596-15](https://doi.org/10.1128/JVI.00596-15).

Copyright © 2015, American Society for Microbiology. All Rights Reserved.
[doi:10.1128/JVI.00596-15](https://doi.org/10.1128/JVI.00596-15)